(Z)-alpha-(羟基亚胺)-2-(三苯甲基氨基)噻唑-4-乙酸乙酯盐酸盐 | 66339-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: (Z)-alpha-(羟基亚胺)-2-(三苯甲基氨基)噻唑-4-乙酸乙酯盐酸盐
• 中文别名: (Z)-[2-(三苯甲基氨基)噻唑-4-基](羟基亚氨基)乙酸乙酯盐酸盐
• 英文名称: 2-(Z)-(Hydroxyimino)-2-<2-<(triphenylmethyl)amino>thiazol-4-yl>acetate hydrochloride
• 英文别名: chlorhydrate d'hydroxyimino-2 Z (tritylamino-2 thiazolyl-4)-2 acetate d'ethyle；ethyl (Z)-2-(2-triphenylmethylaminothiazol-4-yl)-2-(hydroxyimino)acetate hydrochloride；ethyl (Z)-2-hydroxyimino-2-(2-tritylaminothiazol-4-yl)-acetate hydrochloride；ethyl 2-(2-tritylamino-4-thiazolyl)-2-hydroxyimino-acetate hydrochloride；Ethyl (Z)-2-hydroxyimino-2-(2-triphenylmethylaminothiazol-4-yl) acetate hydrochloride；Ethyl (Z)-alpha-(hydroxyimino)-2-(tritylamino)thiazol-4-acetate hydrochloride；ethyl (2Z)-2-hydroxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetate;hydrochloride
• CAS: 66339-00-2
• 化学式: C₂₆H₂₃N₃O₃S*ClH
• 分子量: 494.014
• InChiKey: POPNOGAIIMCRTH-MBANDDHJSA-N

物化性质

• 熔点：
  176-180 °C (dec.)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  5.71
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi

SDS

Name:	Ethyl 2-(2-tritylaminothiazole-4-yl)-2-hydroxyiminoacetate Material Safety Data Sheet
Synonym:	Ethyl (Z)-alpha-(hydroxyimino)-2-(tritylamino)thiazol-4-acetate hydrochlorid
CAS:	66339-00-2

Section 1 - Chemical Product MSDS Name:Ethyl 2-(2-tritylaminothiazole-4-yl)-2-hydroxyiminoacetate Material Safety Data Sheet
Synonym:Ethyl (Z)-alpha-(hydroxyimino)-2-(tritylamino)thiazol-4-acetate hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
66339-00-2	Ethyl 2-(2-tritylaminothiazole-4-yl)-2	97	266-321-5

Hazard Symbols: XN
Risk Phrases: 20/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and if swallowed.Moisture sensitive.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Do NOT get water inside containers. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions.
Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation. Use with adequate ventilation. Do not allow contact with water. Keep from contact with moist air and steam.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 66339-00-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder and chunks
Color: off-white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 174 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C26H23N3O3S.HCl
Molecular Weight: 493.95

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions. May decompose on exposure to moist air or water.
Conditions to Avoid:
Incompatible materials, moisture, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Moisture, water.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 66339-00-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2-(2-tritylaminothiazole-4-yl)-2-hydroxyiminoacetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/22 Harmful by inhalation and if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 66339-00-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 66339-00-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 66339-00-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (Z)-alpha-(羟基亚胺)-2-(三苯甲基氨基)噻唑-4-乙酸乙酯盐酸盐 在 sodium hydroxide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 3.0h， 生成 2-(2-triphenylmethylamino-4-thiazolyl)-2-[Z-(1-methoxy-1-methylethyl)oxyimino]acetic acid
  参考文献：
  名称：

  HR 916 B的合成：头孢菌素的1-（新戊酰氧基）乙基酯的第一个技术上可行的路线

  摘要：

  有效合成头孢菌素头孢菌肟的口服活性1-（RS）-（新戊酰氧基）乙基前药酯HR 916 B（4），并以多千克规模应用。通过在酸性条件下将发酵产物ACA（7）的乙酰氧基与亲核甲醇进行交换来制备AMCA（8）。用混合酸酐14酰化其7-氨基，得到15。分别用碘代醇酯27或溴代醇酯30酯化羧酸15以得到酰基16。同时除去氨基保护基和氧代保护基提供了前药HR 916 3，其通过甲苯磺酸盐4的沉淀得以纯化和稳定。相对于AMCA（8）（四个步骤），总产量4（比率5/6 = 0.65）为39％，相对于ACA（7）（五个步骤）为15％。

  DOI：

  10.1002/jlac.199619961106
• 作为产物：
  描述：

  三苯基氯甲烷 在 三乙胺 作用下， 以 N-甲基乙酰胺 、 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 为溶剂， 生成 (Z)-alpha-(羟基亚胺)-2-(三苯甲基氨基)噻唑-4-乙酸乙酯盐酸盐
  参考文献：
  名称：

  3-Acetoxymethyl-7-(iminoacetamido)-cephalosporanic acid derivatives

  摘要：

  式为##STR1##的化合物，其中R为氢，R'选自含有2至4个碳原子的烯基和炔基的群，A选自氢、碱金属和碱土金属或镁的等效物以及有机胺碱基的群，OR'基位于同位，具有抗生素活性，以及它们的制备方法。

  公开号：

  US04196205A1

文献信息

• [EN] CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES A BASE DE CEPHALOSPORINE GLYCOPEPTIDIQUE RETICULEE
  申请人：THERAVANCE INC

  公开号：WO2003099858A1

  公开（公告）日：2003-12-04

  This invention provides cross-linked glycopeptide - cephalosporin compounds of formula I and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. As a vancomycin analogue is employed in the compounds of the present invention, the point of attachment for the linking moiety is amino acid 7 (AA-7) at position C-29. This position is also sometimes referred to as the '7d' or the 'resorcinol' position of vancomycin. Formula (I)

  这项发明提供了公式I的交联糖肽 - 头孢菌素化合物及其药学上可接受的盐，这些化合物可用作抗生素。该发明还提供了含有这种化合物的药物组合物；使用这种化合物治疗哺乳动物细菌感染的方法；以及用于制备这种化合物的过程和中间体。由于本发明化合物中采用了万古霉素类似物，连接基团的连接点是氨基酸7（AA-7）位于C-29位置。这个位置有时也被称为万古霉素的“7d”或“间苯二酚”位置。公式（I）
• Aminothiazole substituted penicillins and antibacterial compositions
  申请人：Beecham Group P.L.C.

  公开号：US04816452A1

  公开（公告）日：1989-03-28

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or in-vivo hydrolysable ester thereof: ##STR1## wherein R.sup.1 is hydrogen or an amino protecting group and R is substituted methyl; optionally substituted C.sub.2-12 alkyl, alkenyl or alkynyl; carbocyclyl; aryl or heterocyclyl. These compounds have antibacterial properties, and therefore are of use in the treatment of bacterial infections in humans and animals caused by a wide range of organisms.

  本发明提供了一种化合物，其化学式为(I)或其药用可接受的盐或体内可水解酯：其中R.sup.1为氢或氨基保护基，R为取代甲基；可选择取代的C.sub.2-12烷基、烯基或炔基；碳环基；芳基或杂环基。这些化合物具有抗菌性能，因此可用于治疗人类和动物因多种微生物引起的细菌感染。
• 3-substituted-aminomethyl cephalosporin derivatives
  申请人：ICI Pharma

  公开号：US04678781A1

  公开（公告）日：1987-07-07

  A cephalosporin derivative of the formula I: ##STR1## in which X is S, O, CH.sub.2 or SO, R1 is (optionally-substituted)imidazol-2-yl or one of the C-7 acyl groups known in the cephalosporin art, R2 is hydrogen or methoxy, R3 is carboxy or a biodegradable ester thereof and --R4 is of the formula XII, XIII or XIV: ##STR2## in which R32-R40 inclusive are as defined in the specification; and the salts thereof. Pharmaceutical compositions, methods of manufacture and intermediates are also described.

  公式I的头孢菌素衍生物：##STR1##其中X是S、O、CH.sub.2或SO，R1是(可选取代)咪唑-2-基或头孢菌素领域已知的C-7酰基之一，R2是氢或甲氧基，R3是羧基或其可生物降解酯，--R4是公式XII、XIII或XIV：##STR2##其中R32-R40包括如规范中定义的；及其盐。还描述了制药组合物、制造方法和中间体。
• Cephem compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04921851A1

  公开（公告）日：1990-05-01

  This invention relates to a compound of the formula: ##STR1## wherein Q is nitrogen or CH; R.sup.1 is hydrogen or a lower alkyl group which may be substituted; and ring A is a pyridine or pyridazine ring which is substituted at the ring-constituting carbon atom by a group of the formula: --E--(CH.sub.2).sub.n --R.sup.2 in which E is sulfur or NH; R.sup.2 is an amino, carbamoylamino, formylamino, acetylamino, N-formimidoylamino, N-acetimidoylamino, lower alkylamino, hydroxyl or carbamoyloxy group; and n is an integer of 2 to 4, or a pharmaceutically acceptable salt thereof. The compound (I) or a pharmaceutically acceptable sale thereof has excellent antibacterial activity and is used as antibiotics.

  本发明涉及一种化合物，其化学式为：##STR1## 其中Q为氮或CH; R.sup.1为氢或可被取代的低烷基；环A为取代在构成环的碳原子上的公各式为：--E--(CH.sub.2).sub.n --R.sup.2的基团的吡啶或吡嗪环，其中E为硫或NH; R.sup.2为氨基，氨基甲酰基，甲酰氨基，乙酰氨基，N-甲酰亚胺氨基，N-乙酰亚胺氨基，低烷基氨基，羟基或羰氨基氧基；n为2至4的整数，或其药学上可接受的盐。该化合物(I)或其药学上可接受的盐具有优异的抗菌活性，并用作抗生素。
• Cephalosporin antibiotics
  申请人：Glaxo Group Limited

  公开号：US05043334A1

  公开（公告）日：1991-08-27

  Compounds of general formula (I) ##STR1## (where R.sup.1 is a carboxyl group, a group COO.sup..crclbar. or a blocked carboxyl group; R.sup.2 is an amino or protected amino group; and R is hydrogen or a group of the formula CH.sub.2 X, where X represents a halogen atom, a hydroxyl group, an acetoxy group; a group of the formula O.CO.NHR.sup.3, where R.sup.3 is hydrogen, a C.sub.1-4 alkyl group optionally substituted by 1 to 3 halogen atoms or an N-protecting group; a group of the formula OR.sup.4, where R.sup.4 is a C.sub.1-4 alkyl group optionally substituted by halogen or a C.sub.1-4 alkoxy group; or a pyridinium, 3-carbamoyl-pyridinium or 4-carbamoyl-pyridinium group; B is --S-- or --SO-- (.alpha.- or .beta.-); and the dotted line bridging the 2-, 3- and 4- positions indicates that the compound is a ceph-2-em or ceph-3-em compound) and salts thereof, the compounds of formula (I) being associated with an anion when X represents a pyridinium, 3-carbamoylpyridinium group or a 4-carbamoylpyridinium group and R.sup.1 is other than COO.sup..crclbar.) are disclosed. Processes for their preparation and pharmaceutical compositions containing them are also disclosed.

  通式（I）的化合物##STR1##（其中R.sup.1是羧基，COO.sup..crclbar.基团或阻断的羧基基团; R.sup.2是氨基或保护氨基基团; R是氢或公式CH.sub.2 X的基团，其中X代表卤素原子，羟基，乙酰氧基; 公式O.CO.NHR.sup.3的基团，其中R.sup.3是氢，C.sub.1-4烷基，可选地被1到3个卤素原子或N保护基取代; 公式OR.sup.4的基团，其中R.sup.4是C.sub.1-4烷基，可选地被卤素或C.sub.1-4烷氧基取代; 或吡啶铵，3-氨基甲酰基吡啶铵或4-氨基甲酰基吡啶铵基团; B是--S--或--SO--（α-或β-）; 以及连接2-、3-和4-位置的虚线表示该化合物是头孢-2-乙酰基或头孢-3-乙酰基化合物），以及它们的盐，当X表示吡啶铵，3-氨基甲酰基吡啶铵基团或4-氨基甲酰基吡啶铵基团且R.sup.1不是COO.sup..crclbar.时，公式（I）的化合物与阴离子相关。还公开了它们的制备方法和含有它们的制药组合物。